Jeffrey Julkowski

Vergent Bioscience, Inc. develops biotechnology for removal of residual cancer. Its proprietary probe product lights up tumor tissue for the surgeon and serves as a platform for improving the effectiveness of surgical interventions in multiple cancers, including lung, breast, ovarian, colorectal and brain. The company is headquartered in Minneapolis, MN.

Vergent Bioscience, Inc. develops biotechnology for removal of residual cancer. Its proprietary probe product lights up tumor tissue for the surgeon and serves as a platform for improving the effectiveness of surgical interventions in multiple cancers, including lung, breast, ovarian, colorectal and brain. The company is headquartered in Minneapolis, MN.

Vergent Bioscience, Inc. develops biotechnology for removal of residual cancer. Its proprietary probe product lights up tumor tissue for the surgeon and serves as a platform for improving the effectiveness of surgical interventions in multiple cancers, including lung, breast, ovarian, colorectal and brain. The company is headquartered in Minneapolis, MN.

Vergent Bioscience, Inc. develops biotechnology for removal of residual cancer. Its proprietary probe product lights up tumor tissue for the surgeon and serves as a platform for improving the effectiveness of surgical interventions in multiple cancers, including lung, breast, ovarian, colorectal and brain. The company is headquartered in Minneapolis, MN.

Vergent Bioscience, Inc. develops biotechnology for removal of residual cancer. Its proprietary probe product lights up tumor tissue for the surgeon and serves as a platform for improving the effectiveness of surgical interventions in multiple cancers, including lung, breast, ovarian, colorectal and brain. The company is headquartered in Minneapolis, MN.